<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068936</url>
  </required_header>
  <id_info>
    <org_study_id>C1033400</org_study_id>
    <nct_id>NCT03068936</nct_id>
  </id_info>
  <brief_title>IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma</brief_title>
  <official_title>Intensity Modulated Radiotherapy Plus Cisplatin Versus Intensity Modulated Radiotherapy in Patients With Stage 2 Nasopharyngeal Carcinoma: A Phase 3 Multicenter, Open-label, Randomized, Non-inferior Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasopharyngeal carcinoma has high incidence in the southern China, especially in Guangdong&#xD;
      Province. In the world, the standardized morbidity has reached 30/10 million in men while in&#xD;
      women, about 13/10 million. At present, the incidence of nasopharyngeal carcinoma in China&#xD;
      accounted for more than 80% of the world. The cancer-related deaths is in the eighth, which&#xD;
      is a serious threat to our people's health and life. A recent multi-center phase II study of&#xD;
      stage II nasopharyngeal carcinoma showed that: compared with Intensity Modulation&#xD;
      Radiotherapy (IMRT) plus cisplatin, the 3 year local control rate, regional control rate,&#xD;
      distant metastasis-free survival rate and disease-specific survival rate of IMRT were&#xD;
      similar, but the side effects of radiotherapy alone group were lower.&#xD;
&#xD;
      Based on the results of the phase II clinical study, the investigators designed this phase&#xD;
      III clinical study, with the aim to compared the efficacy and toxicity of these two treatment&#xD;
      programs. And finally to provide sufficient evidence for the treatment of stage II&#xD;
      nasopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Refers to the time from included to death due to any cause.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">716</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>IMRT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMRT plus cisplatin group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy),plus synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity modulated radiotherapy</intervention_name>
    <description>Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)</description>
    <arm_group_label>IMRT group</arm_group_label>
    <arm_group_label>IMRT plus cisplatin group</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times</description>
    <arm_group_label>IMRT plus cisplatin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The sex of the subject is not limited, the age is from 18 to 70 years old;&#xD;
&#xD;
          -  Histologically proven nasopharyngeal squamous cell carcinoma, World Health&#xD;
             Organization (WHO) II-III type;&#xD;
&#xD;
          -  Union Internationale Contre le Cancer(UICC) stage 9 clinical stage II patients；&#xD;
&#xD;
          -  Karnofsky score ≥ 80 points;&#xD;
&#xD;
          -  No evidence of distant metastasis;&#xD;
&#xD;
          -  Having an nasopharyngeal MRI before treatment ,which can measure the size of the tumor&#xD;
             in order to analyze the effect.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject had previously suffered from other malignancies (except non-melanotic skin&#xD;
             cancer or cervical carcinoma in situ);&#xD;
&#xD;
          -  Previously received immunotherapy;&#xD;
&#xD;
          -  Previously received chemotherapy;&#xD;
&#xD;
          -  Previously received radiation therapy;&#xD;
&#xD;
          -  Patients who had previously undergone surgical treatment for head and neck tumors&#xD;
             (excluding cervical lymphadenectomy);&#xD;
&#xD;
          -  Evidence of distant metastases or other malignancies at the same time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dehua Wu</last_name>
    <phone>18602062748</phone>
    <email>18602062748@163.com</email>
  </overall_contact>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Intensity modulated radiotherapy</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

